Literature DB >> 35387285

Diabetic ketoacidosis mimicking COVID-19 in an adolescent.

Seyed Javad Boskabadi1, Ali Sharifpour2,3, Zakaria Zakariaei4,3, Elham Sadat Banimostafavi3,5, Mostafa Soleymani3.   

Abstract

Diabetic ketoacidosis (DKA) may be associated with nonspecific symptoms such as dyspnea, tachycardia, anorexia, and vomiting that are similar to COVID-19. We describe an adolescent who was referred to the emergency department with the above symptoms and died after being discharged, regardless of the differential diagnosis and laboratory findings.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID‐19; diabetic ketoacidosis; dyspnea

Year:  2022        PMID: 35387285      PMCID: PMC8978777          DOI: 10.1002/ccr3.5662

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

Coronaviruses are among the most important human pathogens. In late 2019, a new variant of the coronavirus was discovered in Wuhan (Hubei Province, China) as the cause of pneumonia. This new member of the coronavirus family was named COVID‐19. Regardless of age, each individual faces the risk of infection with COVID‐19. The severity of this infection can be asymptomatic, mild, moderate, or severe. COVID‐19 infection may occur with various clinical symptoms. The most common symptoms of this disease include fever, chills, cough, muscle pain, dyspnea, headache, loss of appetite, and gastrointestinal symptoms (such as abdominal pain, nausea, and vomiting). , Asymptomatic infection can only be detected through virological tests and polymerase chain reaction (PCR). In mild cases, nonspecific symptoms such as fever and cough are present, but are not associated with dyspnea, and there is no evidence indicating the COVID‐19 in the CT scans. In moderate infections, nonspecific symptoms are frequently accompanied by imaging evidence and respiratory symptoms (such as dyspnea). Diabetic ketoacidosis (DKA) is one of the most extreme conditions caused by type 1 diabetes and, with less severity, by type 2 diabetes. Ketoacidosis and hyperglycemia are the indicators of DKA. The incidence of DKA is a common manifestation among undiagnosed type 1 diabetes patients. Infections (primarily pneumonia or urinary tract infections), discontinuation of insulin therapy, or insufficient insulin in diabetic patients can all contribute to DKA. DKA may be associated with unspecific symptoms, including dyspnea, tachycardia, loss of appetite, nausea, and vomiting. Several nonspecific symptoms of DKA may be similar to COVID‐19 symptoms (especially among undiagnosed adolescents with type 1 diabetes). Due to the current COVID‐19 pandemic, knowing the difference between COVID‐19 and other diseases that share the symptoms is of great importance. We describe the case of an adolescent boy who was referred to the emergency department (ED) with dyspnea and was discharged after performing a chest X‐ray with a diagnosis of COVID‐19; however, he died regardless of the differential diagnosis of dyspnea and laboratory findings.

CASE PRESENTATION

On April 12, 2021, a 16‐year‐old adolescent boy, a student without a family history of an underlying disease, was referred to the hospital emergency department (ED) in northern Iran with a chief complaint of dyspnea. His dyspnea had become intense from the previous day. The patient had no known underlying diseases, and neither of his parents had any medical or illness history. The primary vital signs of the patient were stable, and tachycardia and tachypnea were not present. Laboratory findings are shown in Table 1. Due to the COVID‐19 pandemic and the onset of the second peak in Iran, considering the incidence of dyspnea and laboratory data reports such as leukocytosis and elevated C‐reactive protein (CRP), the possible primary diagnosis was COVID‐19. Also, PCR sampling was performed for fast confirmation of diagnosis, and a lung computed tomography (CT) scan was requested. Before the PCR test result answer was ready, he was discharged with prescription drugs such as hydrocortisone ampoules (100 mg), adult cold tablets, and diphenhydramine syrup. He was asked to return to the hospital in case of a recurrence of the respiratory symptoms.
TABLE 1

Initial laboratory data in emergency department

Laboratory data parameterResultNormal Range
WBC16 × 103/mm3 4–10103/mm3
PLT265 × 103/mm3 145–450 × 103/mm3
Neutrophils12340/mm3 2500‐8000/mm3
Lymphocytes1360/mm3(12%)1000‐4000/mm3
Hb13 g/dl12.3–15.3 g/dL
BS260 mg/dL90–110 mg/dL
Urea38 mg/dL13–40 mg/dl
Cr1.3 mg/dL0.5–1.3 mg/dL
K3.7 mEq/L3.5–5.5 mEq/L
Na136 mEq/L135–145 mEq/L
C.R.P10+ mg/LLess than 6 mg/L
ESR12mm/hr0–20 mm/hr
LDH295 U/L140–280 U/L
Troponin Q10 ng/dlLess than 100 ng/dl
pH7.307.35–7.45
PCO2 25.4 mmHg35–45 mmHg
HCO3 13mEq/L22–28 mEq/L
Initial laboratory data in emergency department The following morning, the patient was referred to the ED again with complaints including dyspnea and restlessness. The primary vital signs of the patient were as follows: The blood pressure is 120/75 mmHg, the temperature is 37°C, the heart rate is 130 beats/minute, the respiratory rate is 24 breaths/minute, and oxygen saturation is 98%. Considering the vital signs of the patient, he had tachycardia and restlessness. Therefore, an electrocardiogram (ECG) was requested. Due to the severity of the restlessness, the patient did not cooperate with the ECG test. As well, we measured the blood sugar with a glucometer, and the result was reported as 403 mg/dL. The medical history of the patient was obtained through certain questions and a comprehensive history. The patient's mother mentioned that her son had polyuria and polydipsia symptoms in the last ten days. She also stated that the patient had recently lost 10 kg of body weight. Because of the hyperglycemia (blood sugar level of 403 mg/dL) and the symptoms that were suggestive of diabetes, urea, Cr, K, Na, Ca, Mg, Alb, BS, ABG, and ketone body tests were requested. The ABG test result indicated severe metabolic acidosis (Table 2). As a result, DKA was diagnosed, and the patient was transferred to the intensive care unit (ICU).
TABLE 2

Laboratory data in the ICU

Laboratory data parameterResultNormal Range
WBC14 × 103/mm3 4–10 × 103/mm3
PLT265 × 103/mm3 145–450 × 103/mm3
Neutrophils11340/mm3 2500‐8000/mm3
Lymphocytes1260/mm3(9%)1000‐4000/mm3
Hb14 g/dl12.3–15.3 g/dL
BS403 mg/dL90–110 mg/dL
Urea45 mg/dL13–40 mg/dl
Cr1.4 mg/dL0.5–1.3 mg/dL
K3.5 mEq/L3.5–5.5 mEq/L
Na130mEq/L135–145 mEq/L
Calcium9.5 mg/dl8.5–10.5 mg/dl
Mg1.9 mg/dl1.8–2.2 mg/dl
Albumin4 g/dl3.5–5.5 g/dl
P3.1 mg/dl2.5–4.5 mg/dL
C.R.P3+ mg/LLess than 6 mg/L
ESR15 mm/hr0–20 mm/hr
LDH334 U/L140–280 U/L
pH6.417.35–7.45
PCO2 20.4 mmHg35–45 mmHg
HCO3 4.1 mEq/L22–28 mEq/L

Abbreviations: BS, Blood sugar; Cr, Creatinine; CRP, C‐reactive protein; ESR, Erythrocyte Sedimentation Rate; Hb, Hemoglobin; LDH, Lactate dehydrogenase; PLT, Platelet count; WBC, White blood cells.

Laboratory data in the ICU Abbreviations: BS, Blood sugar; Cr, Creatinine; CRP, C‐reactive protein; ESR, Erythrocyte Sedimentation Rate; Hb, Hemoglobin; LDH, Lactate dehydrogenase; PLT, Platelet count; WBC, White blood cells. In the ICU, the patient underwent routine treatment for DKA. The medication included serum N/S (1000 cc), 10 cc KCL 15%, amp ceftriaxone 1 gr BD, insulin regular 5 IU stat, and then 2 IU/h. Due to ABG disorder and decreased consciousness level, anesthesia consultation was also requested. According to the anesthesiologist, the patient did not require mechanical ventilation support, and two vials of bicarbonate were added to his medication. At the next step, cardiovascular counseling was requested. According to the cardiologist's opinion, the patient had no heart complications, and routine DKA management was continued. After 24 h, the PCR test for COVID‐19 was negative. Unfortunately, despite appropriate treatment, the patient's respiratory condition and level of consciousness decreased, and he was intubated, followed by cardiopulmonary arrest, and died after six days. Written informed consent was obtained from the patient's parents for publication of this report. This study was conducted according to the Declaration of Helsinki Principles. Also, CARE guidelines and methodology have been followed in this study.

DISCUSSION

We mentioned a patient who came to the ED with dyspnea complaints. Considering the current pandemic, he was first diagnosed with COVID‐19 and treated as an outpatient. The following day, he returned to the hospital and reported tachycardia and severe dyspnea. According to the accurate medical history obtained, he was diagnosed with diabetic ketoacidosis. The patient was transferred to the ICU, but unfortunately, he died after six days. DKA is the main cause of death among children and adolescents with type 1 diabetes. This condition occurs with a type 1 diabetes diagnosis in almost one‐third of the children in the United States. Ketoacidosis is highly lethal for undiagnosed diabetes patients and can be associated with symptoms including polyuria, polydipsia, loss of appetite, nausea, vomiting, abdominal pain, dyspnea, tachycardia, tachypnea, and eventually coma and death. If the patient has all of the following findings, then the diagnosis of DKA is confirmed , : Blood sugar levels greater than 200 mg/dL (normally, serum glucose concentrations are less than 800 mg/dL and range between 350 and 500 mg/dL) The incidence of metabolic acidosis (pH of venous blood less than 7.3 or bicarbonate less than 15 mmol/L) The presence of ketone bodies in the blood or urine. However, metabolic acidosis is usually the most important finding related to DKA. Our patient indicated all of the mentioned findings (Table 2). Dyspnea was the main clinical complaint of our patient. Dyspnea is a common symptom of ketoacidosis and COVID‐19 infection. In DKA, the body compensates for the metabolic acidosis through hyperventilation and diaphragmatic breathing. This condition is first revealed by an increase in the depth of breath and tachypnea. However, lack of proper medical measures can lead to respiratory muscle fatigue, inadequate ventilation, CO2 retention, and dyspnea. On the other hand, dyspnea is a common finding among COVID‐19 patients. Fever, cough, and dyspnea were the most common symptoms of COVID‐19 patients when they arrived at hospitals, according to various studies. Restlessness and tachycardia were other key findings in our patient. Due to free water loss in DKA, intravascular volume is decreased. Therefore, clinical symptoms linked to intravascular volume decrease, such as tachycardia, poor perfusion of peripheral organs, and poor skin turgor, are common among DKA patients. Such symptoms may overlap with symptoms of other diseases. On the other hand, tachycardia (caused by stress or other factors) and restlessness may also happen in COVID‐19, especially at the early stages of infection. Another reason for our patient's misdiagnosis was the similarity of some of the laboratory findings between COVID‐19 and DKA. Our patient had leukocytosis and an increase in C‐reactive protein (CRP) and lactate dehydrogenase (LDH) levels on the first visit to the ED (Table 1). Laboratory findings in patients with COVID‐19 may differ. In the complete blood count analysis, leukopenia, leukocytosis, and lymphocytopenia have been reported, although the most common manifestation is lymphocytopenia. Also, increased CRP, erythrocyte sedimentation rate (ESR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and LDH can occur. The majority of DKA patients have leukocytosis, pro‐inflammatory cytokine production, and an increase in CRP. This condition is proportional to the degree of ketonemia, is unrelated to infection, and can be caused by an increase in catecholamine. Due to the high number of referrals to the hospital's ED as a result of the COVID‐19 pandemic and the medical centers’ overload, inability to obtain a complete medical history may occur, resulting in inaccurate evaluation and misdiagnosis. In some cases, misdiagnosis may lead to severe complications or even death. Generally, COVID‐19 is associated with multiple nonspecific signs and symptoms. These findings may overlap with other diseases. To confirm the diagnosis of COVID‐19, the complete clinical and laboratory conditions must be considered. In addition to the clinical manifestations and regular laboratory tests, the PCR test is still the best diagnostic option. Eventually, the patient's fate reveals that the clinicians must avoid overreacting to COVID‐19, and besides carefully evaluating the patient's condition, they should also consider the overlapping similar laboratory data, signs, and symptoms of various diseases.

CONCLUSION

Because there are several differential diagnoses for a symptom, a comprehensive history of the patient is required for an accurate diagnosis at the time of admission. Physicians should be aware of the differential diagnosis to avoid misdiagnosis or over‐diagnosis. Consequently, DKA should be considered in the COVID‐19 differential diagnosis, particularly in children, adolescents, and uncontrolled diabetic mellitus patients. Therefore, obtaining an accurate history and urgent approach is essential for appropriate patient management.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

AUTHORSHIPS

SJB and ZZ were involved in the interpretation and collecting of data and editing of the manuscript. ASH and ESB were involved in writing and preparing the final version of the manuscript. MS was responsible for submitting the manuscript. All authors reviewed the paper and approved the final version of the manuscript.

ETHICAL APPROVAL

The study was approved by our local ethics committee.

CONSENT

Written informed consent was obtained from the patient's parents for publication of this report.
  21 in total

1.  Dehydration in children with diabetic ketoacidosis: a prospective study.

Authors:  Maria Sottosanti; Gavin C Morrison; Ram N Singh; Ajay P Sharma; Douglas D Fraser; Khalid Alawi; Jamie A Seabrook; Alik Kornecki
Journal:  Arch Dis Child       Date:  2012-02       Impact factor: 3.791

2.  Incidence Trends of Diabetic Ketoacidosis in Children and Adolescents with Type 1 Diabetes in British Columbia, Canada.

Authors:  Kung-Ting Kao; Nazrul Islam; Danya A Fox; Shazhan Amed
Journal:  J Pediatr       Date:  2020-06       Impact factor: 4.406

3.  Diabetic ketoacidosis: Heralding type 1 diabetes in children.

Authors:  Corinne I Alois; Denise Rizzolo
Journal:  JAAPA       Date:  2017-07

Review 4.  Metabolic acidosis in the intensive care unit.

Authors:  Philippe M Gauthier; Harold M Szerlip
Journal:  Crit Care Clin       Date:  2002-04       Impact factor: 3.598

Review 5.  The extended autonomic system, dyshomeostasis, and COVID-19.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2020-07-22       Impact factor: 4.435

Review 6.  A Literature Systematic Review with Meta-Analysis of Symptoms Prevalence in Covid-19: the Relevance of Olfactory Symptoms in Infection Not Requiring Hospitalization.

Authors:  A Giorli; F Ferretti; C Biagini; L Salerni; I Bindi; S Dasgupta; A Pozza; G Gualtieri; R Gusinu; A Coluccia; Marco Mandalà
Journal:  Curr Treat Options Neurol       Date:  2020-08-28       Impact factor: 3.598

7.  Emergence of a Novel Coronavirus Disease (COVID-19) and the Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak.

Authors:  Matthew J Binnicker
Journal:  Clin Chem       Date:  2020-05-01       Impact factor: 8.327

8.  Suicide due to fear of COVID-19, in the last month of pregnancy, leads to neonatal seizure: A case report.

Authors:  Javad Boskabadi; Saeed Kargar-Soleiman Abad; Shahrokh Mehrpisheh; Elham Pishavar; Roya Farhadi
Journal:  Ann Med Surg (Lond)       Date:  2021-11-24

Review 9.  Extrapulmonary and atypical clinical presentations of COVID-19.

Authors:  Anis Abobaker; Ali Ahmed Raba; Aboubaker Alzwi
Journal:  J Med Virol       Date:  2020-06-29       Impact factor: 20.693

Review 10.  Hematological manifestations of SARS-CoV-2 in children.

Authors:  Chrysoula Kosmeri; Epameinondas Koumpis; Sophia Tsabouri; Ekaterini Siomou; Alexandros Makis
Journal:  Pediatr Blood Cancer       Date:  2020-10-03       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.